Open AccessMass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice
Author(s) -
Jan H. Beumer,
Jianxia Guo,
Evan C. Ray,
Jonas Scemama,
Robert A. Parise,
Berthony Deslouches,
Jonathan D. Steckbeck,
Ronald C. Montelaro,
Julie L. Eiseman
Publication year - 2021
Publication title -
current reviews in clinical and experimental pharmacology
Language(s) - English
Resource type - Journals
eISSN - 2772-4336
pISSN - 2772-4328
DOI - 10.2174/1574884715666200810094201
Subject(s) - antimicrobial , peptide , cationic polymerization , balance (ability) , antimicrobial peptides , chemistry , pharmacology , medicine , microbiology and biotechnology , biochemistry , biology , organic chemistry , physical medicine and rehabilitation
To address multidrug resistance, we developed engineered Cationic Antimicrobial Peptides (eCAPs). Lead eCAP WLBU2 displays potent activity against drug-resistant bacteria and effectively treats lethal bacterial infections in mice, reducing bacterial loads to undetectable levels in diverse organs.